Respiratory syncytial virus (RSV) is a major cause of respiratory illness and hospitalization in older adults during fall and winter in the United States. The 2023-2024 RSV season was the first during which RSV vaccination was recommended for U.S. adults aged ≥60 years, using shared clinical decision-making. On June 26, 2024, the Advisory Committee on Immunization Practices voted to update this recommendation as follows: a single dose of any Food and Drug Administration-approved RSV vaccine (Arexvy [GSK]; Abrysvo [Pfizer]; or mResvia [Moderna]) is now recommended for all adults aged ≥75 years and for adults aged 60-74 years who are at increased risk for severe RSV disease. Adults who have previously received RSV vaccine should not receive another dose. This report summarizes the evidence considered for these updated recommendations, including postlicensure data on vaccine effectiveness and safety, and provides clinical guidance for the use of RSV vaccines in adults aged ≥60 years. These updated recommendations are intended to maximize RSV vaccination coverage among persons most likely to benefit, by clarifying who is at highest risk and by reducing implementation barriers associated with the previous shared clinical decision-making recommendation. Continued postlicensure monitoring will guide future recommendations.

中文翻译：

---

60 岁以上成人使用呼吸道合胞病毒疫苗：免疫实践咨询委员会的最新建议 - 美国，2024 年。


呼吸道合胞病毒 (RSV) 是美国秋季和冬季老年人呼吸道疾病和住院的主要原因。 2023-2024 年 RSV 季节是第一个建议年龄 ≥ 60 岁的美国成年人使用共同临床决策接种 RSV 疫苗的季节。 2024 年 6 月 26 日，免疫实践咨询委员会投票更新了该建议如下：任何美国食品和药物管理局批准的 RSV 疫苗的单剂量（Arexvy [GSK]；Abrysvo [辉瑞]；或 mResvia [Moderna]）现在建议所有年龄 ≥75 岁的成年人以及患有严重 RSV 疾病风险较高的 60-74 岁成年人使用。以前接种过 RSV 疫苗的成年人不应再接种疫苗。本报告总结了这些更新建议所考虑的证据，包括疫苗有效性和安全性的许可后数据，并为 60 岁以上成年人使用 RSV 疫苗提供临床指导。这些更新的建议旨在通过澄清谁处于最高风险并减少与先前共享的临床决策建议相关的实施障碍，最大限度地提高最有可能受益人群的 RSV 疫苗接种覆盖率。持续的许可后监测将指导未来的建议。